These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
594 related articles for article (PubMed ID: 25742208)
1. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. O'Malley SS; Corbin WR; Leeman RF; DeMartini KS; Fucito LM; Ikomi J; Romano DM; Wu R; Toll BA; Sher KJ; Gueorguieva R; Kranzler HR J Clin Psychiatry; 2015 Feb; 76(2):e207-13. PubMed ID: 25742208 [TBL] [Abstract][Full Text] [Related]
2. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial. Oslin DW; Leong SH; Lynch KG; Berrettini W; O'Brien CP; Gordon AJ; Rukstalis M JAMA Psychiatry; 2015 May; 72(5):430-7. PubMed ID: 25760804 [TBL] [Abstract][Full Text] [Related]
3. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Karhuvaara S; Simojoki K; Virta A; Rosberg M; Löyttyniemi E; Nurminen T; Kallio A; Mäkelä R Alcohol Clin Exp Res; 2007 Jul; 31(7):1179-87. PubMed ID: 17451401 [TBL] [Abstract][Full Text] [Related]
4. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A; JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409 [TBL] [Abstract][Full Text] [Related]
5. Association of the Sweet-Liking Phenotype and Craving for Alcohol With the Response to Naltrexone Treatment in Alcohol Dependence: A Randomized Clinical Trial. Garbutt JC; Kampov-Polevoy AB; Kalka-Juhl LS; Gallop RJ JAMA Psychiatry; 2016 Oct; 73(10):1056-1063. PubMed ID: 27627782 [TBL] [Abstract][Full Text] [Related]
6. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). Morley KC; Kranzler HR; Luquin N; Baillie A; Shanahan M; Trent R; Teesson M; Haber PS Trials; 2018 Aug; 19(1):443. PubMed ID: 30115121 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of naltrexone in a community treatment program. Killeen TK; Brady KT; Gold PB; Simpson KN; Faldowski RA; Tyson C; Anton RF Alcohol Clin Exp Res; 2004 Nov; 28(11):1710-7. PubMed ID: 15547458 [TBL] [Abstract][Full Text] [Related]
8. Naltrexone and brief counseling to reduce heavy drinking in hazardous drinkers. Davidson D; Saha C; Scifres S; Fyffe J; O'Connor S; Selzer C Addict Behav; 2004 Aug; 29(6):1253-8. PubMed ID: 15236831 [TBL] [Abstract][Full Text] [Related]
9. A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation Treatment. Kahler CW; Cioe PA; Tzilos GK; Spillane NS; Leggio L; Ramsey SE; Brown RA; O'Malley SS Alcohol Clin Exp Res; 2017 Jun; 41(6):1201-1211. PubMed ID: 28401564 [TBL] [Abstract][Full Text] [Related]
10. Daily relations among affect, urge, targeted naltrexone, and alcohol use in young adults. Bold KW; Fucito LM; Corbin WR; DeMartini KS; Leeman RF; Kranzler HR; O'Malley SS Exp Clin Psychopharmacol; 2016 Oct; 24(5):367-375. PubMed ID: 27690505 [TBL] [Abstract][Full Text] [Related]
11. Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial. Foa EB; Yusko DA; McLean CP; Suvak MK; Bux DA; Oslin D; O'Brien CP; Imms P; Riggs DS; Volpicelli J JAMA; 2013 Aug; 310(5):488-95. PubMed ID: 23925619 [TBL] [Abstract][Full Text] [Related]
12. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. Bogenschutz MP; Ross S; Bhatt S; Baron T; Forcehimes AA; Laska E; Mennenga SE; O'Donnell K; Owens LT; Podrebarac S; Rotrosen J; Tonigan JS; Worth L JAMA Psychiatry; 2022 Oct; 79(10):953-962. PubMed ID: 36001306 [TBL] [Abstract][Full Text] [Related]
13. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Guardia J; Caso C; Arias F; Gual A; Sanahuja J; Ramírez M; Mengual I; Gonzalvo B; Segura L; Trujols J; Casas M Alcohol Clin Exp Res; 2002 Sep; 26(9):1381-7. PubMed ID: 12351933 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016 [TBL] [Abstract][Full Text] [Related]
15. A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients. Guardia J; Roncero C; Galan J; Gonzalvo B; Burguete T; Casas M Addict Behav; 2011 Mar; 36(3):265-9. PubMed ID: 21146937 [TBL] [Abstract][Full Text] [Related]
16. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818 [TBL] [Abstract][Full Text] [Related]